The Medical Letter on Drugs and Therapeutics
ADVANCE
RELEASE
ARTICLE
May 28, 2024
View Complete Issue         Table of Contents 2019 
Vamorolone (Agamree) for Duchenne Muscular Dystrophy
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Vamorolone (Agamree) for Duchenne Muscular Dystrophy
May 28, 2024 (Issue: 5072)
The FDA has approved vamorolone (Agamree – Catalyst), an oral corticosteroid, for treatment of Duchenne muscular dystrophy (DMD) in patients ≥2 years old. Vamorolone is the second oral corticosteroid to be approved in the US for treatment of...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Vamorolone (Agamree) for Duchenne Muscular Dystrophy
Article code: 5072a
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.